Kinnate Biopharma Inc. (Nasdaq: KNTE)(“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global oncology player, today announced their agreement on the sale of exarafenib, the Company’s investigational pan-RAF inhibitor, and other pan-RAF program assets, pursuant to the APA entered into by the parties. This sale of worldwide rights is part of the search for strategic alternatives previously announced by the Company. To know more
